Novartis study shows QTI571 significantly improved walking distance in patients with life-threatening pulmonary arterial hypertension - Seite 3

by terminology such as "potential, " "can, " "estimated, " "committed, " "planned, "
or similar expressions, or by express or implied discussions regarding potential
marketing approvals for QTI571 or regarding potential future revenues from
QTI571. You should not place undue reliance on these statements.  Such forward-
looking statements reflect the current views of management regarding future
events, and involve known and unknown risks, uncertainties and other factors
that may cause actual results with QTI571 to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that QTI571 will be approved for sale in
any market. Nor can there be any guarantee that QTI571 will achieve any
particular levels of revenue in the future. In particular, management´s
expectations regarding QTI571 could be affected by, among other things,
unexpected clinical trial results, including unexpected new clinical data and
unexpected additional analysis of existing clinical data; the company´s ability
to obtain or maintain patent or other proprietary intellectual property
protection; unexpected regulatory actions or delays or government regulation
generally; competition in general; government, industry and general public
pricing pressures; the impact that the foregoing factors could have on the
values attributed to the Novartis Group´s assets and liabilities as recorded in
the Group´s consolidated balance sheet, and other risks and factors referred to
in Novartis AG´s current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Novartis is
providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides healthcare solutions that address the evolving needs of
patients and societies. Focused solely on healthcare, Novartis offers a
diversified portfolio to best meet these needs: innovative medicines, eye care,
cost-saving generic pharmaceuticals, consumer health products, preventive
vaccines and diagnostic tools. Novartis is the only company with leading
positions in these areas. In 2010, the Group´s continuing operations achieved